Cargando…

Pharmacokinetic and dose‐finding studies on efpeglenatide in patients with type 2 diabetes

AIM: To assess the efficacy, safety and pharmacokinetic/pharmacodynamic properties of efpeglenatide, a long‐acting glucagon‐like peptide‐1 receptor agonist, in patients with type 2 diabetes (T2D). RESEARCH DESIGN AND METHODS: Two randomized, double‐blind, placebo‐controlled phase 2 trials were condu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yoon, Kun‐Ho, Kang, Jahoon, Kwon, Se Chang, Trautmann, Michael E., Hompesch, Marcus, Stewart, John, Sorli, Christopher H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7383501/ https://www.ncbi.nlm.nih.gov/pubmed/32175655 http://dx.doi.org/10.1111/dom.14032

Ejemplares similares

Body weight management and safety with efpeglenatide in adults without diabetes: A phase II randomized study
por: Pratley, Richard E., et al.
Publicado: (2019)

Effects of efpeglenatide versus liraglutide on gastric emptying, glucose metabolism and beta-cell function in people with type 2 diabetes: an exploratory, randomized phase Ib study
por: Hompesch, Marcus, et al.
Publicado: (2021)

Efficacy and safety of once‐monthly efpeglenatide in patients with type 2 diabetes: Results of a phase 2 placebo‐controlled, 16‐week randomized dose‐finding study
por: Del Prato, Stefano, et al.
Publicado: (2020)

Efficacy and safety of efpeglenatide in key patient subgroups from the BALANCE randomized trial, stratified by pre-diabetes status, BMI, and age at baseline
por: Pratley, Richard E, et al.
Publicado: (2022)

Safety and Efficacy of Efpeglenatide in Patients With Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials
por: Escobar, Johao, et al.
Publicado: (2023)

Efficacy and Safety of Once-Weekly Efpeglenatide Monotherapy Versus Placebo in Type 2 Diabetes: The AMPLITUDE-M Randomized Controlled Trial
por: Frias, Juan Pablo, et al.
Publicado: (2022)

Accelerated Insulin Pharmacokinetics and Improved Postprandial Glycemic Control in Patients With Type 1 Diabetes After Coadministration of Prandial Insulins With Hyaluronidase
por: Hompesch, Marcus, et al.
Publicado: (2011)

Single‐dose euglycaemic clamp studies demonstrating pharmacokinetic and pharmacodynamic similarity between MK‐1293 insulin glargine and originator insulin glargine (Lantus) in subjects with type 1 diabetes and healthy subjects
por: Crutchlow, Michael F., et al.
Publicado: (2017)

PSUN305 A Double-Blind, Placebo-Controlled Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HM15136 in Obese or Overweight Subjects with Co-morbidities
por: Shin, Wonjung, et al.
Publicado: (2022)

Comparative Pharmacokinetics and Insulin Action for Three Rapid-Acting Insulin Analogs Injected Subcutaneously With and Without Hyaluronidase
por: Morrow, Linda, et al.
Publicado: (2013)

Tolerability of eptinezumab in overweight, obese or type 1 diabetes patients
por: Baker, Brian, et al.
Publicado: (2021)

Device Identification Interoperability in Heterogeneous IoT Platforms †
por: Koo, Jahoon, et al.
Publicado: (2019)

Pharmacokinetics and Pharmacodynamics of High-Dose Human Regular U-500 Insulin Versus Human Regular U-100 Insulin in Healthy Obese Subjects
por: de la Peña, Amparo, et al.
Publicado: (2011)

Adipose tissue measurement in clinical research for obesity, type 2 diabetes and NAFLD/NASH
por: Vilalta, Adrian, et al.
Publicado: (2022)

Pharmacokinetic and pharmacodynamic bioequivalence between regular human insulin (rDNA origin) in 0.9% sodium chloride ready‐to‐use infusion 1 U/mL and 100 U/mL concentrate diluted to 1 U/mL in healthy males
por: Hompesch, Marcus, et al.
Publicado: (2021)

Identifying and meeting the challenges of insulin therapy in type 2 diabetes
por: Sorli, Christopher, et al.
Publicado: (2014)

Population pharmacokinetics and dose optimization of vancomycin in neonates
por: Lee, Soon Min, et al.
Publicado: (2021)

The Outbreak of COVID-19 and Diabetes in Korea: “We Will Find a Way as We Have Always Done”
por: Won, Kyu Chang, et al.
Publicado: (2020)

Peritoneal Nebulization of Ropivacaine during Laparoscopic Cholecystectomy: Dose Finding and Pharmacokinetic Study
por: Allegri, Massimo, et al.
Publicado: (2017)

Population pharmacokinetics of vancomycin in obesity: Finding the optimal dose for (morbidly) obese individuals
por: Smit, Cornelis, et al.
Publicado: (2020)

Optimal dose finding of garenoxacin based on population pharmacokinetics/pharmacodynamics and Monte Carlo simulation
por: Tanigawara, Yusuke, et al.
Publicado: (2011)

Dose‐finding methods for Phase I clinical trials using pharmacokinetics in small populations
por: Ursino, Moreno, et al.
Publicado: (2017)

Population pharmacokinetics and dosing optimization of metformin in Chinese patients with type 2 diabetes mellitus
por: Li, Ling, et al.
Publicado: (2020)

First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus
por: Kapur, Anita, et al.
Publicado: (2013)

Phase 1 dose-finding and pharmacokinetic study of eribulin-liposomal formulation in patients with solid tumours
por: Evans, T. R. Jeffry, et al.
Publicado: (2019)

Pharmacokinetic and dose‐finding study of osimertinib in patients with impaired renal function and low body weight
por: Fujiwara, Yutaka, et al.
Publicado: (2023)

Pharmacodynamic Effects of Canagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor, from a Randomized Study in Patients with Type 2 Diabetes
por: Sha, Sue, et al.
Publicado: (2014)

Pharmacokinetics and Optimal Dosing of Phenobarbital
por: Shareef, Safiullah, et al.
Publicado: (2018)

Dose Finding of Lenvatinib in Subjects With Advanced Hepatocellular Carcinoma Based on Population Pharmacokinetic and Exposure–Response Analyses
por: Tamai, Toshiyuki, et al.
Publicado: (2017)

Application of Physiologically‐Based and Population Pharmacokinetic Modeling for Dose Finding and Confirmation During the Pediatric Development of Moxifloxacin
por: Willmann, Stefan, et al.
Publicado: (2019)

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of Empagliflozin in Patients with Type 2 Diabetes Mellitus
por: Heise, Tim, et al.
Publicado: (2013)

Influence of Obesity and Type 2 Diabetes Mellitus on the Pharmacokinetics of Tramadol After Single Oral Dose Administration
por: Porażka, Joanna, et al.
Publicado: (2019)

Pharmacokinetics of intravenous administered two different high doses of ascorbic acid in healthy beagle dogs
por: Lim, Seula, et al.
Publicado: (2019)

Comparative single-dose pharmacokinetics of sildenafil after oral and rectal administration in healthy beagle dogs
por: Yang, Hyuck-Joo, et al.
Publicado: (2018)

Pharmacokinetics of Oral Prednisone at Various Doses in Dogs: Preliminary Findings Using a Naïve Pooled-Data Approach
por: Sebbag, Lionel, et al.
Publicado: (2020)

A phase I dose-finding, pharmacokinetics and genotyping study of olaparib and lurbinectedin in patients with advanced solid tumors
por: Poveda, Andres, et al.
Publicado: (2021)

4512 Allopregnanolone Dose Finding for Status Epilepticus Treatment by Pharmacokinetic-Pharmacodynamic Modeling using Quantitative EEG in Dogs
por: Patterson, Edward “Ned”, et al.
Publicado: (2020)

Imeglimin population pharmacokinetics and dose adjustment predictions for renal impairment in Japanese and Western patients with type 2 diabetes
por: Tomita, Yoshiko, et al.
Publicado: (2022)

Intraocular Pharmacokinetics of 10-fold Intravitreal Ranibizumab Injection Dose in Rabbits
por: Kim, Hyeong Min, et al.
Publicado: (2020)

Single‐Dose and Multiple‐Dose Pharmacokinetics of Vaniprevir in Healthy Men
por: Caro, L, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_rs00utau6afm2re90nupcj6rem